|
|
Vol. 13.29 – 5 December, 2024
|
|
|
|
|
|
|
|
39 healthy female pigs, divided into four groups, were ventilated for 48 hours with high or low mechanical power; and high or low targeted fluid balance. [American Journal of Respiratory and Critical Care Medicine]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
|
|
Using a preclinical model of chronic experimental asthma, investigators demonstrated that rhinovirus-induced exacerbations increased prostaglandin D2 release, mucus production, transforming growth factor-β1 and type-2 inflammation.
[Nature Communications]
|
|
|
|
|
|
The expression of ficolin-1 in the plasma of idiopathic pulmonary fibrosis and connective tissue disease- interstitial lung disease patients was first determined.
[Journal of Translational Medicine]
|
|
|
|
|
|
Researchers performed preclinical studies on the combination of pirfenidone with vinorelbine, or with vinorelbine plus carboplatin, in NSCLC.
[International Journal of Cancer]
|
|
|
|
|
|
The authors analyzed the interaction of primary fibroblasts and alveolar type 2 (AT2) pneumocytes in an organoid model. Single-cell analysis, histology, and qRT-PCR revealed that fibroblasts expressing high levels of fibrosis markers regulated IL-6/activator of transcription-3 signaling in AT2 cells. [Molecular Medicine]
|
|
|
|
|
|
Scientists found that coiled-coil domain-containing 34 (CCDC34) may be associated with lung adenocarcinoma stemness through weighted gene co-expression network analysis.
[Cancer Gene Therapy]
|
|
|
|
|
|
Researchers hypothesized that ErbB4 deletion affected the ultrastructure of alveolar epithelial type II cells, specifically lamellar bodies and the intracellular distribution of the immunomodulating hydrophilic surfactant proteins (SP)-A and the hydrophobic SP-B. [Experimental Lung Research]
|
|
|
|
|
|
|
|
The authors summarize the current understanding of how exposure to fine particulate matter (PM2.5 ) induces lung carcinogenesis and accelerates lung cancer development.
[EMBO Molecular Medicine]
|
|
|
|
|
|
Scientists explore the efficacy and safety of combining radiotherapy with immunotherapy in the treatment of stage IV NSCLC, delving into the intricacies of their underlying mechanism. [Current Treatment Options in Oncology]
|
|
|
|
|
|
|
|
Merus, N.V. announced that the US FDA approved BIZENGRI®, a treatment indicated for adults with pancreatic adenocarcinoma or NSCLC that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. [Merus, N.V.]
|
|
|
|
|
|
|
|
January 26-29, 2025 San Diego, California, United States
|
|
|
|
|
|
|
|
|
|
|
University of Bradford – Bradford, England, United Kingdom
|
|
|
|
|
|
|
Northwell Health – Manhasset, New York, United States
|
|
|
|
|
|
|
Max Planck Institute – Bad Nauheim, Hessen
|
|
|
|
|
|
|
Cedars Sinai – Los Angeles, California, United States
|
|
|
|
|
|
|
Cancer Research UK – Manchester, England, United Kingdom
|
|
|
|
|
|